Clinical Trials Logo

Clinical Trial Summary

The prevalence of cutaneous pruritus among hemodialysis patients is about 50% to 80%. There is only a handful of studies on the itchy skin of hemodialysis patients and the findings are to be validated. Effective drugs to treat cutaneous pruritus are not available yet. Hence, the purpose of the study is to eliminate the uremic toxins from the intestinal tract using AST-120 as a treatment measure to improve the symptom of the hemodialysis patients' cutaneous pruritus and discuss and assess its effectiveness. For this, the investigators will recruit 150 patients to validate the application potential of the AST-120 in the cutaneous pruritus brought about by uremia.


Clinical Trial Description

Uremic toxins, such as indoxyl sulfate (IS) and p-cresol, or p-cresyl sulfate (PCS), are markedly accumulated in the organs of chronic kidney disease (CKD) patients. These toxins can induce inflammatory reactions and enhance oxidative stress, prompting glomerular sclerosis and interstitial fibrosis, to aggravate the decline of renal function. Consequently, uremic toxins play an important role in the worsening of renal and cardiovascular functions. Furthermore, they destroy the quantity and quality of bone. Oral sorbent AST-120 reduces serum levels of uremic toxins in CKD patients by adsorbing the precursors of IS and PCS generated by amino acid metabolism in the intestine. Accordingly, AST-120 decreases the serum IS levels and reduces the production of reactive oxygen species by endothelial cells, to impede the subsequent oxidative stress. This slows the progression of cardiovascular and renal diseases and improves bone metabolism in CKD patients. Although large-scale studies showed no obvious benefits from adding AST-120 to the standard therapy for CKD patients, subsequent sporadic studies may support its use. Pruritus is a common and distressing symptom that affects patients with chronic kidney disease (CKD). Indoxyl sulfate (IS) and p-cresyl sulfate (PCS) are uremic toxins with similar protein binding, dialytic clearance, and proinflammatory features. The pathogenesis of uremic pruritus is not well elucidated, although it is theorized that inflammation may play a role. Elevated levels of C-reactive protein (CRP), interleukin-6, and interleukin-2 have been found among patients on hemodialysis suffering from pruritus, which may also partly explain the association the investigators found between low hemoglobin levels and a higher prevalence of pruritus, given the association between low hemoglobin and inflammatory states. Since the pathophysiology of uremic pruritus is multifactorial. Subclinical or overt uremic neuropathy, skin or nerve inflammation in the context of kidney failure-associated chronic systemic inflammation, or an increase in activity of μ-opioid receptors due to kidney failure have all been implicated. A large, international study demonstrated the prevalence of moderate-to-extreme pruritus among patients with end-stage kidney disease on hemodialysis to be approximately 40% and was associated with a higher prevalence of comorbid conditions, worse biochemical profiles, poorer mental and physical quality of life, a higher probability of depression, and poorer sleep quality and survival. More recently, this prevalence was shown to range from 26% in Germany to 48% in the United Kingdom. Other studies have also demonstrated an association between pruritus and worse kidney disease burden scores, poorer health-related quality of life, and greater frequency of sleep disturbances in patients on dialysis. However, pruritus is often overlooked by health care providers within dialysis units. In dialysis facilities where 21%-50% of patients reported having severe pruritus, only 1% of medical directors estimated this same prevalence. This may be due, in part, to underreporting by patients, as 17% of patients who were nearly always or always bothered by pruritus had not reported their symptoms to any health care provider. Uremic pruritus intensity is also associated with multiple health-related quality-of-life outcomes, such as sleep quality, mood, and social function, and is independently associated with mortality. Uremic pruritus has been identified as a key research priority by patients with kidney disease. Although several small studies have examined a variety of interventions, the efficacy of these interventions and the optimal treatments remain poorly defined. To address this important knowledge gap, the investigators systematically reviewed the literature and summarized the evidence for the major interventions for the treatment of uremic pruritus. The investigators will choose AST-120 as therapeutic agents for uremic pruritus. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04639674
Study type Interventional
Source Conmed Pharmaceutical & Bio-Medical Corporation
Contact
Status Completed
Phase Phase 4
Start date July 2, 2020
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04728984 - A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet Phase 3
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01660243 - Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis Phase 2
Completed NCT06159686 - The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus Phase 1/Phase 2
Not yet recruiting NCT05525234 - A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus Phase 4
Completed NCT03002233 - TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus Phase 1
Completed NCT03998163 - CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Recruiting NCT05885737 - Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus Phase 3
Recruiting NCT04393675 - Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients Phase 1/Phase 2
Completed NCT03576235 - Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients N/A
Completed NCT05575193 - Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis N/A
Completed NCT02858726 - Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 2/Phase 3
Completed NCT02143648 - Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Completed NCT00494975 - The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease N/A
Completed NCT03758079 - Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus Phase 4
Completed NCT02229929 - Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Phase 2
Completed NCT03636269 - CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Completed NCT04711603 - A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. Phase 3
Completed NCT02696499 - Treatment of Uremic Pruritus With PA101B Phase 2
Completed NCT03422653 - A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) Phase 3